Objective To assess the current status of microbial and parasitic quality control for laboratory animals in Jiangxi Province by analyzing microbiological and parasitic test results from production facilities between 2020 and 2024, and to provide a basis for enhancing quality control measures. MethodsIn accordance with the current national standards for laboratory animals at the time of testing, the Jiangxi Provincial Laboratory Animal Quality Inspection Station (affiliated to Institute of Occupational Medicine of Jiangxi) conducted microbial and parasitic testing on 451 laboratory animals of 4 species from 6 laboratory animal production units in Jiangxi Province between 2020 and 2024, and analyzed the quality status of laboratory animals in the province. ResultsPasteurella pneumotropica was detected in one mouse sample in 2020, with a detection rate of 5.00%. Pseudomonas aeruginosa was detected in one mouse sample and mouse hepatitis virus antibody was detected in another mouse sample in 2023, with a detection rate of 2.78%, respectively. No microorganisms or parasites that should be excluded from SPF grade mice as specified in the national standards were detected in 2021, 2022, or 2024, with a qualification rate of 100.00%. Pasteurella pneumotropica was detected in four rat samples in 2020, with a detection rate of 20.00%. Pseudomonas aeruginosa was detected in two rat samples in 2021, with a detection rate of 10.00%, and Tyzzer's disease agent antibody was detected in four rat samples in 2024, with a detection rate of 10.00%. No microorganisms or parasites that should be excluded from SPF grade rats as specified in the national standards were detected in 2022 or 2023, with a qualification rate of 100.00%. For rabbits and guinea pigs, no microorganisms or parasites required to be tested for conventional grade rabbits and guinea pigs as specified in the national standards were detected from 2020 to 2024, with the qualification rate of both species reaching 100.00%. ConclusionBased on the microbial and parasitic testing results, the quality of rabbits and guinea pigs in Jiangxi Province is satisfactory. However, some issues persist with rats and mice. It is recommended to enhance the quality of experimental animals in Jiangxi Province by increasing the frequency of random inspections by quality testing units or by improving the self-inspection capabilities of production and user facilities.

OBJECTIVE To conduct a clinical comprehensive evaluation of five marketed thrombopoietin receptor agonists （TPO-RA） approved in China， providing quantitative evidence for drug selection and therapeutic decision-making in medical institutions. METHODS Relevant data on Romiplostim for injection， Eltrombopag olamine tablets， Herombopag olamine tablets， Avatrombopag maleate tablets， and Lusutrombopag tablets were collected. Based on the Chinese Rapid Guide for Drug Evaluation and Selection in Medical Institutions （Second Edition）， 12 formulations of these five TPO-RA were scored quantitatively and comparatively across five dimensions： pharmacological characteristics， efficacy， safety， cost-effectiveness， and other attributes. RESULTS The comprehensive scores of the 12 formulations ranged from 62.56 to 75.50 points， with most scoring ≥70 points. Using the highest-scoring formulation for each generic name as a representative， the overall rankings of the five TPO-RA were as follows： Lusutrombopag tablets （75.50 points）， Eltrombopag olamine tablets （75.10 points）， Avatrombopag maleate tablets （70.40 points）， Romiplostim for injection （63.93 points）， and Herombopag olamine tablets （63.52 points）. Lusutrombopag tablets scored relatively high in pharmacological characteristics， safety， and cost-effectiveness， while Eltrombopag olamine tablets performed well in efficacy and cost-effectiveness. The other formulations showed varying scores across evaluation dimensions. CONCLUSIONS The five TPO-RA demonstrate favorable overall clinical value， with Lusutrombopag tablets and Eltrombopag olamine tablets ranking higher in comprehensive scores， these two drugs should be prioritized in drug selection and formula optimization by medical institutions.

Background/Aims: Non-pharmacological treatments are crucial for managing irritable bowel syndrome (IBS), yet patient engagement remains a challenge. Understanding patients' knowledge, attitudes, and practices regarding these treatments is essential for improving care. Methods: A cross-sectional study was conducted across 5 hospitals, from October 2023 to February 2024. A self-designed knowledge, attitudes, and practices questionnaire along with the IBS quality of life and IBS severity scoring system was administered, and 496 valid responses were analyzed. Statistical analyses included correlation tests, multivariate linear regression, and mediation effect analysis. Results: The median scores for knowledge, attitude, and practice were 28, 25.5, and 21, respectively. Significant positive correlations were found between knowledge-attitude (r = 0.195), knowledge-practice (r = 0.364), and attitude-practice (r = 0.151). The multivariate linear regression analysis further indicated that knowledge (β = 0.399, P < 0.001) and attitude (β = 0.219, P = 0.022) positively correlated with the practical performance. SEM revealed that knowledge had a significant direct effect on both attitude (β = 0.186, P = 0.013) and practice (β = 0.356, P = 0.006). However, the direct effect of attitude on practice was not significant, and attitude did not mediate the relationship between knowledge and practice. Conclusions IBS patients exhibit a significant gap between their positive attitudes and their actual practices concerning non-pharmacological treatments. Knowledge is a direct driver of practice, but positive attitudes alone are insufficient to translate into behavior. Healthcare providers must move beyond simply fostering positive attitudes and focus on targeted educational interventions that provide actionable knowledge and skills to improve patient outcomes.

Objective:To analyze the etiological composition and clinical characteristics of infant hypertension，and provide reference for its diagnosis and treatment.Methods:This is a retrospective case-control study.Retrospective investigation and analysis were conducted on the clinical data of infants discharged from Beijing Children's Hospital Affiliated to Capital Medical University with a diagnosis of "hypertension" from June 1，2016 to September 30，2021，including clinical manifestations，auxiliary examinations，treatment plans，and prognosis.Results:A total of 74 eligible children were collected，including 42 male infants（56.8%）and 32 female infants（43.2%）.A total of 67 cases（90.5%）had clear secondary factors，including 35 cases of kidney disease（47.3%），12 cases of connective tissue disease（16.2%），and 9 cases of hematological tumor disease（12.2%）.At the beginning of the disease，cardiac ultrasound showed that 54 cases（73.0%）had ventricular wall thickening，including mild thickening in 31 cases（57.4%），moderate thickening in 11 cases（20.3%），and severe thickening in 12 cases（22.2%）.After grouping by etiology，the incidence of proteinuria and severe hypertension in the renal hypertension group，as well as those receiving multiple antihypertensive drugs，was significantly higher than that in the non-renal hypertension group（ χ 2=28.493， P<0.001； χ 2=17.283， P<0.001； χ 2=17.358， P<0.001）；Renal disease was risk factor for severe hypertension in infants according to univariate and multivariate logistic regression analysis respectively（ OR=11.176，95% CI：2.882~43.339， P<0.001； OR=11.669，95% CI：2.921~46.624， P<0.001）.Thirty-one children had follow-up records for 6 months or more，and 13（41.9%）still required antihypertensive treatment，of whom 26（83.9%）were no longer recorded as having elevated blood pressure. Conclusion:Infant hypertension is mainly secondary，with a high proportion of renal factors and predisposition to severe hypertension，which requires multiple antihypertensive drugs for control.Active antihypertensive treatment and removal of secondary factors during the acute phase are helpful for controlling hypertension in infants，but further research is needed on treatment options and long-term prognosis.

Objective:To develop the Adolescent Mental Health Computerized Adaptive Test(AMH-CAT)for assessing psychological crises in adolescents using item response theory(IRT).Methods:A total of 8 679 students,aged 9 to 19 years,were sampled from 14 primary and secondary schools.The item bank was constructed by examining unidimensionality,independence,discrimination,and Differential Item Functioning(DIF).The AMH-CAT algorithm was developed using R software and validated for reliability and validity through real and simulated data.The School Psychological Interview Evaluation Form served as the criterion tool to assess the predictive validi-ty of AMH-CAT in evaluating psychological crises levels.Results:The item bank,consisting of 43 items,demon-strated unidimensionality and independence,with discrimination values＞0.80 and no DIF across genders.Under va-rious stopping rules,AMH-CAT showed ABS values＜0.40,RMSE values＜0.50,and a correlation(r)＞0.87(P＜0.001)between estimated and true psychological crises levels.Real participants answered an average of 10 items under the SE(θ)≤0.4 stopping rule,with a reliability of 0.89,and the scores were positively correlated with the complete item bank scores(r=0.95,P＜0.001).The predictive accuracy for Level 1 and Level 2 concerns was 0.89 and 0.90,respectively.Conclusion:The Adolescent Mental Health Computerized Adaptive Test(AMH-CAT)demonstrates excellent validity,reliability and assessment efficiency for evaluating adolescent psychological crises.

Diabetic retinopathy, one of the microvascular complications of diabetes, has become a leading cause of blindness in developed countries.The disease's pathogenesis is complex and involves inflammation and oxidative stress, which eventually lead to retinal microvascular disease and neurodegenerative changes.A large body of clinical and basic research evidence shows that metformin can improve diabetic retinopathy and delay its onset and progression.Metformin exerts protective effects on retinal microangiopathy and retinal cells via AMP-activated protein kinase-dependent and -independent pathways.Metformin can improve retinal cell autophagy, apoptosis and senescence by reducing the oxidative stress response and regulating mitochondrial energy metabolism.Metformin clinical and basic research provides a new approach to treating diabetic retinopathy and a potential direction for developing drugs.This article reviews the progress of clinical and basic research on metformin's protective effects against diabetic retinopathy.

Objective:To summarize clinical and genotypic features, treatment, and prognosis of children with Dent disease.Methods:A retrospective case-series study was conducted on 15 children with Dent disease at the Nephrology Department of Beijing Children′s Hospital, Capital Medical University from January 2008 to June 2024.The patients were divided into a type Ⅰ Dent disease group and a type Ⅱ Dent disease group according to the type of mutated genes.The clinical and genotypic characteristics, treatment, and prognosis were described.Then, the treatment effect of the disease was analyzed using the t-test or Wilcoxon rank-sum test. Results:All 15 children were boys, and the average onset age was 4.45 years.The illness struck each child insidiously at first, and it was complicated by nephrolithiasis/nephrocalcinosis (66.7%), short stature (46.7%), and rickets (20.0%).There was no significant difference in urine protein or calcium levels between the 2 groups.However, the type Ⅰ Dent group had more severe clinical symptoms than the type Ⅱ Dent group.Renal biopsy results indicated that lesions affected both tubules and glomeruli.The children were diagnosed with thylakoid hyperplasia, glomerulosclerosis, and in certain cases, glomerular adhesions, pedunculated fusions, and crescents.Of the 15 children, 11 had CLCN5 gene variations, and 4 had OCRL gene variations.Five mutants found in this study were reported for the first time.Up to the end of the follow-up, 24-hour urinary calcium[0.26 (0.22, 0.36) mmol/(kg·d) vs.(0.12±0.05) mmol/(kg·d), P<0.001], Ratio of urine calcium to creatinine[(0.36±0.16) mg/mg vs.(0.26±0.13) mg/mg, P=0.043], 24-hour urinary protein[74.34 (65.63, 79.26) mg/(kg·d) vs.59.88 (56.77, 64.23) mg/(kg·d), P=0.002], and urinary β2-microglobulin/creatinine levels[33.85 (12.26, 43.37) vs.(10.47±7.55) mg/mg, P=0.001] after treatment were significantly lower than those before treatment.The differences in urinary protein/creatinine and urinary α1-microglobulin/creatinine levels were not significant before and after treatment.Two children in the type Ⅰ Dent group experienced a progressive deterioration in renal function during follow-up, and they progressed to chronic kidney disease (CKD) stages 3 and 5, respectively. Conclusions:Dent disease can affect both tubules and glomeruli.The clinical symptoms of type Ⅰ Dent disease are severer than type Ⅱ Dent disease.Dent disease, mainly brought on by mutations in the CLCN5 gene.Whole-exon gene testing is an effective method of validating a diagnosis and helps in early detection, classification, and treatment of Dent disease.There is currently no specific treatment available for this disease.Symptomatic treatment can reduce urine calcium and protein levels and rectify electrolyte imbalances, but it may not prevent further impairment of renal function.Most children have normal kidney function and a good prognosis, with a small percentage progressing to CKD.

Objective:To summarize and analyze the clinical and genetic characteristics of children with nephronophthisis (NPHP) so as to improve clinicians′ understanding of this disease and provide reference for its early diagnosis.Methods:Retrospective case series study.The clinical and genetic data of 15 children with NPHP diagnosed by gene detection in the Department of Nephrology, Beijing Children′s Hospital, Capital Medical University from January 2016 to June 2024 were retrospectively analyzed.Non-normal distribution measurement data were expressed as median (range) and analyzed by rank sum test.Results:There were 10 boys and 5 girls in the 15 patients included, with a median age of onset of 6.85 years (1.16-14.00 years).The initial clinical manifestations were lack of specificity, and most patients presented non-specific symptoms such as fatigue, growth retardation, polydipsia and polyuria initially.At the first visit, 14 children had renal function damage, and 5 of them had end-stage renal disease (ESRD).Another 4 children progressed to ESRD during the follow-up, and 2 children died during the follow-up.The median age of ESRD or death was 12.25 years (1.87-15.00 years).Renal ultrasound changes were observed in all 15 children, including parenchymal echo enhancement in 14 cases, unclear medullary boundary in 10 cases, renal cysts in 7 cases, and renal volume reduction in 2 cases.Renal histopathological examination was performed in 2 cases, and their results were consistent with the pathological manifestations of early and late NPHP, respectively.NPHP can be complicated with renal, intracranial, cardiac and other extrarenal manifestations. NPHP1, NPHP4, NPHP2, NPHP3, NPHP11, NPHP13 and NPHP18 mutations were detected in 5, 4, 2, 1, 1, 1, and 1 patient, respectively.Previously unreported mutation sites were revealed, including c. 594-3C>G, c.1415T>C, c.37553769delTTCGGGGGACACAGA, c.4067A>C, c.1196A>G, c.4140+ 3G>C, c.1196A>G, c.2101-20A>C, c.643C>T and c. 2087T>C. Conclusions:The onset of NPHP is insidious and it often presents with non-specific manifestations.Laboratory and imaging examinations lack specificity.Generally, renal insufficiency is an early symptom of NPHP, and it progresses rapidly, resulting in poor prognosis.Most patients lose the opportunity for kidney biopsy.NPHP should be considered in children with early onset and unexplained renal insufficiency, and genetic testing is helpful for early diagnosis.

Objective:To estimate the radiation dose to caregivers and the public from 177Lu- peptide receptor radionuclide therapy (PRRT) for pediatric neuroblastoma patients and determine the duration of contact restrictions, in order to provide a reference for relevant radiation protection measures. Methods:A retrospective study was conducted by collecting data from 18 pediatric neuroblastoma patients, aged between 3 and 13 (6.72±2.72), who received 177Lu-1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid-D-Phe1-Tyr3-Thr8-octreotide (DOTATATE) treatment at the Nuclear Medicine Department of Shandong Cancer Hospital from June 2023 to July 2023. Absorbed dose rate in air at 0, 0.1, 0.5, 1 and 2 m from the patients was measured using a radiation-survey at 1, 4, 24, 48 and 96 h after administration. The whole-body region of interest was delined using HERMES software. Subsequently, curve regression fitting was performed using a biexponential function model. By incorporating hypothesized social contact durations, the effective doses received by family members and the public in contact with patients were estimated. Additionally, MIM software was used to outline the whole-body VOI to obtain the total volume of lesions, and the Pearson or Spearman correlation coefficient was employed to analyze the relationship between the absorbed dose rate in air and clinical indicators as well as the total volume of lesions. Results:The 177Lu-DOTATATE administration dose was (4 353.42±1 451.51) MBq. All patients were discharged from hospital 24 h after 177Lu-DOTATATE administration. At the time of discharge, patients had excreted (76.70±3.99)% of the administered activity, and the absorbed dose rate in air at 0.1, 1 and 2 m from the patients were (32.74±6.98), 3.68(3.01, 4.70) and (1.22±0.51) μSv/h, respectively. After being discharged, the radiation doses to caregivers from children aged 2-5 years and 5-13 years were (2.47±1.80) mSv and (0.88±0.47) mSv, respectively. The contact restriction duration was 2 d for nighttime sleeping with family members and 1 d for contact with other children. On the day of discharge, patients should limit their time on public transportation within 4 h and do not need to restrict private transportation. Conclusions:To ensure the effective dose kept within the safety limits stipulated by current regulations, it is necessary to implement contact restrictions for patients’ family members and the public. After implementing preventive measures, 177Lu-DOTATATE treatment is a safe radionuclide therapeutic option.

Objective To investigate the effect of ginsenoside Re on angiotensin Ⅱ(Ang Ⅱ)-induced proliferation,migration,and phenotype transformation of vascular smooth muscle cells(VSMCs)by regulating the Ras homologous gene family member A(RhoA)/mitogen activated protein kinase(MAPK)pathway.Methods MOVAS cells were divided into control group,Ang Ⅱ group,ginsenoside Re low dose group,ginsenoside Re medium dose group,ginsenoside Re high dose group,andginsenoside Re high dose+RhoA activator(U46619)group.MOVAS cell proliferation was detected by CCK-8.MOVAS cell migration was detected by scratch assay.Immunocytochemistry was used to detect the positive expression of α-smooth muscle actin(α-SMA)and osteopontin(OPN)proteins in MOVAS cells.qRT-PCR was used to detect the mRNA expression of PCNA,MMP-9,and MMP-2 in MOVAS cells.Western blot was used to detect RhoA,phosphorylated extracellular signal regulated kinase 1/2(p-ERK1/2),phosphorylated stress activated protein kinase 1(p-JNK1),and p-P38 protein in MOVAS cells.Results Compared with the control group,the OD450 value,scratch healing rate,OPN protein positive expression,PCNA,MMP-9,MMP-2 mRNA expression,RhoA,p-ERK1/2,p-JNK1,p-P38 protein expression of MOVAS cells in the Ang II group increased,while the positive expression of α-SMA protein decreased significantly(P<0.05).Compared with the Ang Ⅱ group,the OD450 value,scratch healing rate,OPN protein positive expression,PCNA,MMP-9,MMP-2 mRNA expression,and RhoA,p-ERK1/2,p-JNK1,and p-P38 proteins of MOVAS cells in the low,medium,and high dose groups of ginsenoside Re decreased,while the positive expression of α-SMA protein increased.The trend was most significant in the high dose group of ginsenoside Re(P<0.05).Compared with ginsenoside Re high-dose group,OD450 value,scratch healing rate,OPN protein positive expression,PCNA,MMP-9,MMP-2 mRNA expression and RhoA,p-ERK1/2,p-JNK1,p-P38 protein in ginsenoside Re high-dose+U46619 group increased,the positive expression of α-SMA protein decreased significantly(P<0.05).Conclusion Ginsenoside Re may inhibit the proliferation,migration,and phenotype transformation of Ang Ⅱ in MOVAS cells by suppressing the RhoA/MAPK pathway.